An Open-label, Non-randomized, Multicenter Phase I Study to Determine the Maximum Tolerated or Recommended Phase II Dose of Oral Mutant IDH1 Inhibitor BAY1436032 and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic and Anti-tumor Activity in Patients With IDH1-R132X-mutant Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2018
At a glance
- Drugs BAY 1436032 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bayer
- 02 Feb 2018 Planned End Date changed from 2 Feb 2019 to 1 Jun 2019.
- 02 Feb 2018 Planned primary completion date changed from 2 Dec 2018 to 27 Mar 2019.
- 10 Jun 2017 Biomarkers information updated